SODIUM-DEPENDENT GLUCOSE CO-TRANSPORTER 2 (SGLT 2) MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

SODIUM-DEPENDENT GLUCOSE CO-TRANSPORTER 2 (SGLT 2) MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is expected to register a CAGR greater than 11% over the forecast period 2022 - 2027.

The Sodium-Dependent Glucose Cotransporter 2 market benefited from the COVID-19 pandemic. People with diabetes have a weakened immune system, which is exacerbated by COVID-19. Diabetes patients are more likely than non-diabetics to have significant problems. Diabetic medicine makers took care during COVID-19 to ensure that pharmaceuticals were delivered to diabetes patients with the assistance of local governments. "Since the start of COVID-19, our commitment to patients, our employees, and the communities where we operate has remained unchanged," NovoNordisk stated on their website. "We continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19."

SGLT-2 inhibitors, commonly known as gliflozins, are a kind of medication used to treat type 2 diabetes by lowering high blood glucose levels. SGLT-2 inhibitors have an important role in the management of cardiovascular risk factors such as blood pressure, glycemia, weight, cardiac function, and antiinflammatory action. Diabetic medications have been proposed as prospective treatments for diabetic people infected with SARS-CoV-2 during the COVID-19 epidemic. Technological advancements have increased over the period leading to several modifications either in the SGLT-2 inhibitors or the formulations being developed.

Therefore, due to increased prevalence and the aforementioned factors, the studied market is anticipated to witness growth over the analysis period.

Key Market TrendsJardiance is Leading the SGLT2 Market.

Jardiance, which was released globally in 2014, is a once-daily oral medication that is used to control blood glucose levels in people with type-2 diabetes. Jardince is gaining sales when compared to Invokana, with patients preferring this drug, as it has a lower risk of cardiovascular diseases when compared to other SGLT2 drugs, by helping the kidneys remove glucose from the bloodstream. Jardiance accounted for more than 30% of the sales in the global SGLT2 class of drugs in 2021.

Jardiance is a prescription medicine used to lower blood sugar along with diet and exercise in adults with type 2 diabetes. It reduces the risk of cardiovascular death in adults with type 2 diabetes who also have known cardiovascular disease. Jardiance also reduces the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, when the heart cannot pump enough blood to the rest of the body. It is not for people with type 1 diabetes.

65% of the Market Share is Occupied by North America.

North America accounts for the highest type- 2 diabetic population. The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. Prices are comparatively high in this region. Jardiance holds 50% of the market share in the US SGLT2 market. The American Diabetes Association Standards of Care has recommended empagliflozin (the active pharmaceutical ingredient in Jardiance) as the only diabetic drug that reduces the risk of cardiovascular death in adults with Type-2 diabetes. In the United States, the prevalence of diabetes has increased dramatically during the last two decades, a fact driven by the increased prevalence of obesity and lifestyle changes. Diabetes ranks among the fast-growing chronic diseases in the United States. About 1.75 million US citizens are diagnosed with diabetes every year. The country also has the highest obese population, which is a prominent cause of Type 2 diabetes.

Competitive Landscape

The Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market is highly consolidated, with a few significant manufacturers having a global market presence. The companies strengthen their market presence by getting approval in new forms.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.